AUPH earnings analysis
What we found in AUPH's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Aurinia Pharmaceuticals reported strong Q1 2026 results with total revenue of $77.7 million, which represents a 24% increase year-over-year. Notable growth was driven by robust net product sales of LUPKYNIS at $73.6 million, up 23% from the prior year, and a significant rise in operating cash flow to $32.6 million. EPS increased substantially to $0.25 from $0.16 in Q1 2025, reflecting improved profitability.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Robust Revenue Growth
- Total revenue reached $77.7 million, up 24% from $62.5 million in Q1 2025.
- Strong LUPKYNIS Sales
- Net product sales of LUPKYNIS were $73.6 million, a 23% increase from $60 million year-over-year.
- Significant EPS Increase
- Diluted EPS rose to $0.25 from $0.16 in Q1 2025.
- High Gross Margin
- Gross margin improved to 92% in Q1 2026, compared to 86% in Q1 2025.
- Substantial Operating Cash Flow
- Operating cash flow surged to $32.6 million, a 2408% increase from $1.3 million in Q1 2025.
- Positive Net Income Growth
- Net income was $34.4 million, up from $23.3 million in Q1 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- High Cash Outflows
- Cash outflows from financing activities were $53.7 million, impacting liquidity.
- Uncertainties in Product Demand
- Dependence on LUPKYNIS sales amidst competitive biopharmaceutical landscape.
- Market Risks from Regulatory Changes
- Potential regulatory risks may affect future product sales and operational stability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.25
- Gross margin
- 92%
- Operating margin
- 53.2%
What they said about what is next.
Aurinia reaffirmed its 2026 revenue guidance, estimating $315M to $325M.
The filing reads better than the one before it.
What came before.
- 10-K · February 26, 2026
- Aurinia reports continued commercial momentum for LUPKYNIS with 2025 net product sales of $271.3 million (up 25% vs. $216.2M in 2024), materially stronger operating cash flow of $135.7 million (up 206% vs. $44.4M in…
- 10-Q · November 4, 2025
- Aurinia reported Q3 revenue of $73,468,000 and GAAP diluted EPS of $0.23, both up materially versus the year-ago quarter. Net product sales drove the beat ($70,627,000 vs $55,503,000 a year ago) while…
- 10-Q · May 12, 2025
- Aurinia delivered a strong Q1 2025 quarter: revenue of $62.465M (up $12.162M or ~24.2% YoY), a swing to operating income of $21.847M (vs. an operating loss of $13.253M in Q1 2024) and diluted EPS of $0.16. Operating…
- 10-K · February 27, 2025
- Aurinia reported strong commercial traction for LUPKYNIS with net product sales of $216.2M in 2024, up 36% from $158.5M in 2023, and positive operating cash flow of $44.4M versus $(33.5)M in 2023. The company finished…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AUPH makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever